UNSPSC 51332878: Trifluoperazine dihydrochloride

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6P1Y2SNF5V, chemically known as 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine dihydrochloride, but more generally known as trifluoperazine dihydrochloride, which bears US NIH Compound Identifier 5566.

European Medicines Agency schedules trifluoperazine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG. Most nations, for tariff purposes, schedule trifluoperazine dihydrochloride under HS 29343090. SMILES: CN1CCN(CC1)CCCN2C3CCCCC3SC4C2CC(CC4)C(F)(F)F.CL.CL.

UNSPSC 51332878 Trifluoperazine dihydrochloride is a Commodity code that state and local procurement offices use to classify pharmaceutical products and active pharmaceutical ingredients. The recent opportunities block shows minimal alignment between the code's nominal scope and actual purchasing activity; the single recent opportunity posted is Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems, which are distinct products unrelated to trifluoperazine dihydrochloride. State and local procurement activity under this specific code appears limited or mislabeled in current public records.

Seminole County's IFB 60459723LAS, posted June 30, 2026 with a response deadline of July 26, 2023, solicits 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for delivery to the Seminole County Community Health Building in Sanford, Florida. The contract structure includes an initial two-year term with a one-year renewal option, fixed-fee pricing, quarterly deliveries, and potential FEMA funding with accompanying federal compliance requirements. No explicit set-aside designations are stated. The substantial date mismatch in the record (posted June 30, 2026 but response deadline July 26, 2023) suggests data integrity issues in the underlying opportunity. Given the code–opportunity mismatch and the scarcity of recent relevant solicitations, this code does not present a clear procurement pipeline under its stated pharmaceutical scope.